Evidence map›Paper›PMID 40452837›Full record

SynthesisFrontiers in oncology2025

Prognostic value of the systemic immune-inflammation index in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

Guorong Chen, Bahu Bao, Yucai Ye, Aoyan Hu, Jingzi Sun, Weiying Liu

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guorong ChenDepartment of Respiratory Medicine, The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Bahu BaoDepartment of Respiratory Medicine, The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Yucai YeDepartment of Respiratory Medicine, The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Aoyan HuDepartment of Respiratory Medicine, The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Jingzi SunDepartment of Respiratory Medicine, The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Weiying LiuDepartment of Respiratory and Critical Care Medicine, the First Hospital of Lanzhou University, Lanzhou, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although the systemic immune-inflammation index (SII) has emerged as a potential prognostic marker in various cancers, its specific role in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy remains insufficiently explored. To address this critical gap, we conducted a comprehensive meta-analysis to assess the prognostic value of SII in NSCLC patients treated with immune checkpoint inhibitors (ICIs). Method: A comprehensive search was conducted across multiple databases-including PubMed, EMBASE, Cochrane and Web of Science-to identify relevant studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of SII for survival outcomes. Result: Ten studies involving a total of 1,547 patients were included. High systemic immune-inflammation index (SII) was significantly associated with worse overall survival (OS) (HR=1.44, 95% CI=1.21-1.70, p < 0.001; I²=3.8%) and progression-free survival (PFS) (HR=1.44, 95% CI=1.21-1.71, p < 0.001; I²=37.2%). Subgroup analysis indicated that an SII >792 was significantly associated with poorer OS and PFS. Conclusion: High SII is significantly associated with poorer OS and PFS, particularly when SII >792. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024586791, identifier RD42024586791.

Indexed as

immune checkpoint inhibitorsmeta-analysisnon-small cell lung cancersurvivalsystemic immune-inflammation index

Identifiers

PMID40452837
PMCPMC12122344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.